TABLE 1.
Antimicrobial susceptibility profiles of wild-type K. oxytoca and K. oxytoca OXY-2 hyperproducer strains evaluated in this study
| Isolate | MIC (μg/ml) of the indicated drugs to K. oxytoca isolatesa
|
|||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AMK | GEN | AMP | SAM | AMC | FEP | CRO | CAZ | CXM | CEF | CIP | MEZ | TZP | PIP | TIM | CTT | SXT | ATM | IPM | MER | |
| 7 | 16 | >8 | >16 | >16/8 | >16/8 | 1 | 1 | 2 | >16 | >16 | 2 | >64 | >64/2 | >64 | >64/2 | 4 | >2/38 | >256 | 0.25 | 0.25 |
| 6 | 8 | 4 | >16 | >16/8 | >16/8 | 1 | 2 | 2 | >16 | >16 | 2 | >64 | >64/4 | >64 | >64/2 | 8 | >2/38 | >256 | 0.5 | 0.25 |
| 5 | 16 | >8 | >16 | >16/8 | >16/8 | 2 | 8 | 2 | >16 | >16 | 8 | >64 | >64/4 | >64 | >64/4 | 32 | >2/38 | >256 | 0.25 | 0.25 |
| 4 | 16 | 1 | >16 | >16/8 | >16/8 | 1 | 2 | 1 | >16 | >16 | 2 | >64 | >64/4 | >64 | >64/4 | 4 | >2/38 | >256 | 0.5 | 0.25 |
| 3 | 2 | 4 | >16 | >16/8 | >16/8 | 1 | 2 | 1 | >16 | >16 | 2 | >64 | >64/4 | >64 | >64/4 | 4 | >2/38 | >256 | 0.5 | 0.25 |
| 2 | 16 | 4 | >16 | >16/8 | >16/8 | 1 | 1 | 2 | >16 | >16 | 2 | >64 | >64/4 | >64 | >64/4 | 4 | >2/38 | >256 | 0.5 | 0.25 |
| 1 | 8 | 2 | >16 | >16/8 | >16/8 | 1 | 1 | 2 | >16 | >16 | 2 | >64 | >64/4 | >64 | >64/4 | 4 | >2/38 | >256 | 0.5 | 0.25 |
a
MIC values were determined by broth microdilution technique (3). AMK, amikacin; AMC, amoxicillin-clavulanic acid; SAM, ampicillin-sulbactam; AMP, ampicillin; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; CEF, cephalothin; CIP, ciprofloxacin; GEN, gentamicin; IPM, imipenem; MER, meropenem; ATM, aztreonam; MEZ, mezlocillin; TZP, piperacillin-tazobactam; PIP, piperacillin; TIM, ticarcillin-clavulanic acid; CTT, cefoxitin; SXT, trimethoprim-sulfamethoxazole.